Loading stock data…
$1.58-0.11 (-6.51%)
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Cabaletta Bio, Inc. in the Healthcare sector is trading at $1.58 with a market capitalization of $268M. Wall Street consensus targets $13.25 (8 analysts), implying a +738.6% move over the next 12 months. The stock is currently near its 52-week low of $1.56, remaining 45.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$52.02M↓ | -$44.30M↓ | -$42.61M↑ | -$46.59M↓ | -$45.91M |
| Net Income | -$51.02M↓ | -$43.52M↓ | -$41.92M↑ | -$44.87M↑ | -$45.13M |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-s...